“Backed by Science” – What does it Mean?

“有科學依據”是什麼意思？

許多公司銷售“有科學依據”的產品，但無論作為科學家還是非科學家，想要去鑑定這些科學證據的質量都可能十分困難。

在科學/證據方面，與其它國家相比，我們在新西蘭的產品包裝上所能展示的內容受到限制。我們現行的法規制定於 20 世紀 80 年代，早已過時。

在加拿大等國家，我們可以根據支持我們產品的科學依據以及完善的註冊流程，提出截然不同的聲明，這種流程既能保障消費者安全，又能支持功效型產品的銷售。

在研發既有效又安全的產品時，在科學和技術層面有許多需要考量的地方：

  1. 哪些生物活性成分有最好的證據支持我們想要達到的健康成果？
  2. 這些生物活性成分如何協同作用——它們是互補的還是拮抗的？
  3. 我們如何將這些生物活性成分製成某種劑型，使其在整個生產過程中保持生物活性？
  4. 我們如何去除黴菌和酵母，同時又不破壞成分的生物活性？這尤其重要，因為購買產品的客戶往往是免疫功能受損的人群。
  5. 我們以何種形式呈現產品，使其既方便使用，又能保持穩定和有效？
  6. 我們信任哪些原料/生物活性成分供應商，以確保我們的生物活性成分來源安全且高質量？
  7. 我們如何持續改進產品，並對其進行技術和臨床測試？

我們引以為豪的是，我們非常重視產品背後的科學與技術質量。

我們並沒有止步不前，目前正在生理學家和肺科醫生的支持下設計合作臨床試驗，以收集關於我們 Zestt Breathe+ 系列產品的進一步科學數據——我們將在今年年底前獲得結果。

我們還與最高質量的原料供應商合作，例如 Blis Technologies，他們的口腔益生菌產品背後擁有廣泛的科學研究支持。以下是我們所使用的兩種口腔益生菌成分 BlisK12 和 BlisM18 所依託的部分科學研究參考資料。我們在 Zestt Breathe+ 和 Zestt Gut+ 含片中使用 BlisK12，在 Zestt Cardio+ 含片中使用 BlisM18。我們在 Zestt Oral+ 含片中同時使用了 BlisK12 和 BlisM18（這是我們所知的唯一一款同時含有這兩種口腔益生菌的產品）。

如果您想了解更多關於這些研究的信息，請隨時告訴我們。

  1. Di Pierro, F., Donato, G., Fomia, F., Adami, T., Careddu, D., Cassandro, C., & Albera, R. (2012). Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. International Journal of General Medicine, 5, 991–997. https://doi.org/10.2147/IJGM.S38859
  2. Di Pierro, F., Adami, T., Rapacioli, G., Giardini, N., & Streitberger, C. (2013). Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opinion on Biological Therapy, 13(3), 339–343. https://doi.org/10.1517/14712598.2013.758711
  3. Di Pierro, F., Colombo, M., Zanvit, A., Risso, P., & Rottoli, A. S. (2014). Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Drug, Healthcare and Patient Safety, 6(1), 15–20. https://doi.org/10.2147/dhps.s59665
  1. Di Pierro, F., Colombo, M., Zanvit, A., & Rottoli, A. S. (2016). Positive clinical outcomes derived from using Streptococcus salivarius K12 to prevent streptococcal pharyngotonsillitis in children: a pilot investigation. Drug, Healthcare and Patient Safety, 8, 77 -81. https://doi.org/10.2147/DHPS.S117214
  2. Di Pierro, F., Colombo, M., Giuliani, M. G., Danza, M. L., Basile, I., Bollani, T., Conti, A. M., Zanvit, A., & Rottoli, A. S. (2016). Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. European Review for Medical and Pharmacological Sciences, 20(21), 4601–4606.
  3. Di Pierro, F., Risso, P., Poggi, E., Timitilli, A., Bolloli, S., Bruno, M., Caneva, E., Campus, R., & Giannattasio, A. (2018). Use of Streptococcus salivarius K12 to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children: A retrospective analysis in not-recurrent pediatric subjects. Minerva Pediatrica, 70(3), 240–245. https://doi.org/10.23736/ S0026-4946.18.05182-4
  4. Gregori, G., Righi, O., Risso, P., Boiardi, G., Demuru, G., Ferzetti, A., Galli, A., Ghisoni, M., Lenzini, S., Marenghi, C., Mura, C., Sacchetti, R., & Suzzani, L. (2016). Reduction of group A beta-hemolytic streptococcus pharyngotonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Therapeutics and Clinical Risk Management, 12, 87. https://doi.org/10.2147/TCRM.S96134
  5. Marini, G., Sitzia, E., Panatta, M. L., & de Vincentiis, G. C. (2019). Pilot study to explore the prophylactic efficacy of oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngo-tonsillar episodes in pediatric patients. International Journal of General Medicine, 12, 213–217. https://doi.org/10.2147/IJGM.S168209
  6. Wang, Q., Lin, X., Xiang, X., Liu, W., Fang, Y., Chen, H., Tang, F., Guo, H., Chen, D., Hu, X., Wu, Q., Zhu, B., & Xia, J. (2021). Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study. Frontiers in Bioengineering and Biotechnology, 9. https://doi.org/10.3389/fbioe.2021.646184
  1. Campanella, V., Syed, J., Santacroce, L., Saini, R., Ballini, A., & Inchingolo, F. (2018). Oral probiotics influence oral and respiratory tract infections in pediatric population: a randomized double-blinded placebo-controlled pilot study. European Review for Medical and Pharmacological Sciences, 22(22), 8034–8041. https://doi.org/10.26355/ EURREV_201811_16433
  2. Guo, H., Xiang, X., Lin, X., Wang, Q., Qin, S., Lu, X., Xu, J., Fang, Y., Liu, Y., Cui, J., & Li, Z. (2022). Oropharyngeal Probiotic ENT-K12 as an Effective Dietary Intervention for Children With Recurrent Respiratory Tract Infections During Cold Season. Frontiers in Nutrition, 9. https://doi.org/10.3389/ fnut.2022.900448
  1. Di Pierro, F., & Colombo, M. (2021). The administration of S. salivarius K12 to children may reduce the rate of SARS-CoV-2 infection. In Minerva Medica (Vol. 112, Issue 4, pp. 514–516). Edizioni Minerva Medica. https://doi.org/10.23736/S0026-4806.21.07487-5
  1. Di Pierro, F., Iqtadar, S., Mumtaz, S. U., Bertuccioli, A., Recchia, M., Zerbinati, N., & Khan, A. (2022). Clinical Effects of Streptococcus salivarius K12 in Hospitalized COVID-19 Patients: Results of a Preliminary Study. Microorganisms, 10(10), 1926. https://doi.org/10.3390/microorganisms10101926
  1. La Torre, F., Sota, J., Insalaco, A., Conti, G., del Giudice, E., Lubrano, R., Breda, L., Maggio, M. C., Civino, A., Mastrorilli, V., Loconte, R., Natale, M. F., Celani, C., Romeo, M., Patroniti, S., Gentile, C., Vitale, A., Caggiano, V., Gaggiano, C., … Rigante, D. (2023). Preliminary data revealing efficacy of Streptococcus salivarius K12 (SSK12) in Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome: A multicenter study from the AIDA Network PFAPA syndrome registry. Frontiers in Medicine, 10. https://doi.org/10.3389/ fmed.2023.1105605
  1. Laws, G. L., Hale, J. D. F., & Kemp, R. A. (2021). Human Systemic Immune Response to Ingestion of the Oral Probiotic Streptococcus salivarius BLIS K12. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12602-021-09822-3
  2. Laws, G. A., Harold, L. K., Tagg, J. R., & Hale, J. D. F. (2022). Interferon Gamma Response in Human Saliva Following Exposure to the Oral Probiotic Streptococcus salivarius BLIS K12. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/ S12602-022-10010-0
  1. Bertuccioli, A., Gervasi, M., Annibalini, G., Binato, B., Perroni, F., Rocchi, M. B. L., Sisti, D., & Amatori, S. (2023). Use of Streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomised double-blind study. Frontiers in Immunology, 14. https://doi.org/10.3389/ 2023.1129060
  2. Burton, J. P., Chilcott, C. N., Moore, C. J., Speiser, G., & Tagg, J. R. (2006). A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. Journal of Applied Microbiology, 100(4), 754–764. https://doi.org/10.1111/j.1365-2672.2006.02837.x
  3. Jamali, Z., Aminabadi, N. A., Samiei, M., Deljavan, A. S., Shokravi, M., & Shirazi, S. (2016). Impact of chlorhexidine pretreatment followed by probiotic streptococcus salivarius strain K12 on halitosis in children: A randomised controlled clinical trial. Oral Health and Preventive Dentistry, 14(4), 305–313. https://doi.org/10.3290/j.ohpd.a36521
  4. Hu, L., Mao, Q., Zhou, P., Lv, X., Hua, H., & Yan, Z. (2019). Effects of Streptococcus salivarius K12 with nystatin on oral candidiasis—RCT. Oral Diseases, 25(6), 1573–1580. https://doi.org/10.1111/odi.13142
  5. Poorni, S., Nivedhitha, M., Srinivasan, M., & Balasubramaniam, (2022). Effect of Probiotic Streptococcus salivarius K12 and M18 Lozenges on the Cariogram Parameters of Patients With High Caries Risk: A Randomised Control Trial. https://doi.org/10.7759/cureus.23282
  6. Tandelilin, ReginaT. C., Widita, E., Agustina, D., & Saini, R. (2018). The effect of oral probiotic consumption on the caries risk factors among high-risk caries population. Journal of International Oral Health, 10(3), 132. https://doi.org/10.4103/ jioh_82_18
  7. Benic, G. Z., Farella, M., Morgan, X. C., Viswam, J., Heng, N. C., Cannon, R. D., & Mei, L. (2019). Oral probiotics reduce halitosis in patients wearing orthodontic braces: a randomized, triple-blind, placebo-controlled trial. Journal of Breath Research, 13(3), 36010. https://doi.org/10.1088/1752-7163/ AB1C81
  8. Bardellini, E., Amadori, F., Gobbi, E., Ferri, A., Conti, G., & Majorana, A. (2020). Does streptococcus salivarius strain M18 assumption make black stains disappear in children? Oral Health and Preventive Dentistry, 18(2), 161–164. https://doi.org/10.3290/j.ohpd.a43359
  9. Salim, H. P., Mallikarjun, S. B., Raju, S., & Surendranath, R. (2023). Randomized Clinical Trial of Oral Probiotic Streptococcus salivarius M18 on Salivary Streptococcus mutans in Preprimary Children. International Journal of Clinical Pediatric Dentistry, 16(2), 259–263. https://doi.org/10.5005/jpjournals-10005-2527
  10. Burton, J. P., Drummond, B. K., Chilcott, C. N., Tagg, J. R., Thomson, W. M., Hale, J. D. F., & Wescombe, P. A. (2013). Influence of the probiotic Streptococcus salivarius strain M18 on indices of dental health in children: A randomized double-blind, placebo-controlled trial. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.056663-0
  11. Di Pierro, F., Zanvit, A., Nobili, P., Risso, P., & Fornaini, C. (2015). Cariogram outcome after 90 days of oral treatment with Streptococcus salivarius M18 in children at high risk for dental caries: results of a randomized, controlled study. Clinical, Cosmetic and Investigational Dentistry, 7, 107–113. https://doi.org/10.2147/CCIDE.S93066
  12. Scariya, L., Nagarathna, D. v, & Varghese, M. (2015). Probiotics in periodontal therapy. International Journal of Pharma and Bio Sciences, 6(1), P242-P250.
  13. Kiselnikova, L. P., & Toma, E. I. (2022). 長期攝入益生菌對齲齒學齡前兒童主要牙科參數的影響。《兒科牙科與牙科預防》，22(2)，97–102。 https://doi.org/10.33925/1683-3031-2022-22-2-97-102
  14. Babina, K., Salikhova, D., Doroshina, V., Makeeva, I., Zaytsev, A., Uvarichev, M., Polyakova, M., & Novozhilova, N. (2023). 含唾液鏈球菌M18菌株的口腔益生菌對牙齦炎和牙菌斑的緩解作用：一項隨機臨床試驗。《營養素》，15(18)，3882。https://doi.org/10.3390/nu15183882
  15. Burleigh, M. C., Rosier, B. T., Simpson, A., Sculthorpe, N., Henriquez, F., & Easton, C. (2023). 益生菌唾液鏈球菌M18可增加血漿亞硝酸鹽水平但不會改變血壓：一項試點隨機對照試驗。《應用微生物學》，3(3)，774–785。 https://doi.org/10.3390/ applmicrobiol3030054
  16. Burton, J. P., Wescombe, P. A., Moore, C. J., Chilcott, C. N., & Tagg, J. R. (2006). 口腔益生菌唾液鏈球菌的安全性評估，《應用與環境微生物學》。 https://doi.org/10.1128/AEM.72.4.3050-3053.2006
  1. Burton, J. P., Chilcott, C. N., Wescombe, P. A., & Tagg, J. R. (2010). 口腔益生菌唾液鏈球菌的擴展安全性數據，《益生菌與抗菌蛋白》，2(3)，135–144。 https://doi.org/10.1007/s12602-010-9045-4
  1. Burton, J. P., Cowley, S., Simon, R. R., McKinney, J., Wescombe, P. A., & Tagg, J. R. (2011). 口腔益生菌唾液鏈球菌K12的安全性與人體耐受性評估：一項隨機、安慰劑對照、雙盲研究。《食品與化學毒理學：英國工業生物研究協會國際期刊》，49(9)，2356–2364。 https://doi.org/10.1016/j.fct.2011.06.038
  1. Burton, J. P., Wescombe, P. A., Macklaim, J. M., Chai, M. H. C., MacDonald, K., Hale, J. D. F., Tagg, J., Reid, G., Gloor, G. B., & Cadieux, P. A. (2013). 口腔益生菌唾液鏈球菌M18的持續性具有劑量依賴性，且巨型質粒轉移可增強其細菌素生產和粘附特性。《公共科學圖書館：綜合》，8(6)。https://doi.org/10.1371/journal.pone.0065991

祝好，Anna 和 Darcy。

如果您想進一步討論相關內容，請聯繫 Darcy 或 Anna（電話分別為 +64 27 599 2255 或 +64 27 4861418），或發送郵件至 info@zesttwellness.com。

返回網誌